Go To Content

The initiative is a large-scale clinical genetic research project conducted by the Academia Sinica in collaboration with 13 medical center-level hospitals in Taiwan.


In recent years, the number of patients with chronic diseases has been increasing due to population aging. Countries around the world have begun to promote and develop precision medicine, such as the All of Us Research Program in the US, the Precision Medicine Catapult in the UK, and the Genomic Medicine in France. In the modern era of booming genetic analysis technology, precision medicine has become a new trend in medical care development worldwide. The TMU healthcare system is participating in the second phase of the TPMI project. Superintendent Dr. Jeng-Fong Chiou (邱仲?) of the TMU Taipei Cancer Center is the principal investigator, and TMU Hospital Superintendent Dr. Ray-Jade Chen (陳瑞杰), Wanfang Hospital Superintendent Dr. Ta-Liang Chen (陳大樑), and Shuang-Ho Hospital Superintendent Dr. Mai-Szu Wu (吳麥斯) are co-PIs. 50,000 subjects will be recruited to participate in the project.


TPMI project is key to the development of precision medicine for clinical application. It collects Taiwanese specific data and builds a Taiwanese genetic database so that bioinformatics research teams can use AI for big data analysis and accelerate the discovery of the risk factors of adverse drug reactions and diseases common to Taiwanese. Therefore, the Initiative will not only promote the health of the Taiwanese people and reduce medical costs, but also contribute to the sustainable development of precision medicine, biological big data and biomedicine.

TMU will simultaneously receive from the Academia Sinica precision medical and genetic analysis-related equipment worth about NT$20 million. Dr. Jeng-Fong Chiou said that with the advancement in genetic testing technology, information hidden in the genes can be slowly analyzed and decoded, and data with very high reference value for treatment or prevention can be further predicted. Such precision medical testing is expected to improve the medical care quality and medication safety of the TMU Healthcare System and even throughout Taiwan.